+66% since picked: Which pharma stock did our AI pick before a 30% earnings beat?

Amneal Pharmaceuticals (NASDAQ:AMRX) was selected by an AI model as a promising mid-cap pharma stock back on June 1, 2026. Since then, the stock has seen a +66.74% increase in value. The AI recognized growth potential in Amneal, as indicated by a PEG ratio of 0.35, suggesting the market had not yet fully acknowledged the company's earnings momentum.

By mid-October 2026, Amneal had already demonstrated strong fundamentals. The company reported adjusted EPS of $0.30, surpassing analyst consensus by 30.4%. Revenue for the quarter came in at $796 million, up 10% year-over-year and 5% above forecasts. Simultaneous with these results, the FDA removed a prior safety warning on estradiol patches and approved two of Amneal's denosumab biosimilars, signaling a surge in demand for the company's products.

This strategic positioning by the AI, which began on June 1, 2026 and yielded a +66.74% return before the mainstream news broke, was reinforced by these positive events. Amneal Pharmaceuticals continues to trade near its 52-week high, reflecting sustained accumulation over the past five months.